
Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial
Betsy Goodfellow | July 25, 2023 | News story | Medical Communications | Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial
Bavarian Nordic has announced that its phase 3 clinical trial of MVA-BN, its respiratory syncytial virus (RSV) vaccine candidate for adults over the age of 60, did not meet all of its primary endpoints for preventing lower respiratory tract disease (LRTD) following RSV infection.
The study results showed that the vaccine has a 59% efficacy at preventing more than two pre-defined LRTD symptoms, meaning it met one of the efficacy criteria of the trial. However, the vaccine was only 42.9% effective at preventing severe LRTD based on more than three pre-defined symptoms, therefore missing the co-primary endpoint of the trial.
The company is now planning to discontinue its RSV programme, including its partnership with Nuance Pharma.
Paul Chaplin, president and chief executive officer of Bavarian Nordic, commented: “We are disappointed that our RSV vaccine candidate was not successful in this pivotal trial. While this outcome was unexpected and will impact our short-term growth expectations, we continue to have a unique commercial business and given the recent strong brand and market growth, this provides a solid foundation for profitable growth in the years to come.”
Betsy Goodfellow
Related Content

BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …






